Drug intelligence / Profile preview

anti-botulinum toxin recombinant hyperimmune

Development stage: Preclinical
Lead developer: GigaGen
Modality: Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Administration: Intravenous

Overview

Anti-botulinum toxin recombinant hyperimmune is a preclinical-stage recombinant polyclonal antibody therapy being developed by GigaGen (a subsidiary of Grifols) for the treatment and prevention of botulinum toxin poisoning and biothreat exposure. Developed under contracts with the U.S. Department of Defense (DOD) and the Biomedical Advanced Research and Development Authority (BARDA), the therapeutic is designed to neutralize all seven botulinum neurotoxin (BoNT) variants (serotypes A through G). Utilizing GigaGen's proprietary single-cell recombinant polyclonal antibody platform, the drug replicates and enhances the natural antibody diversity of immunized donors, offering a highly potent, laboratory-manufactured alternative to scarce plasma-derived hyperimmune products.

Other names: anti-botulinum toxin recombinant polyclonal hyperimmunerecombinant anti-botulinum toxin hyperimmune

Targets

BoNT/G (Botulinum neurotoxin type G)BoNT/F (Botulinum neurotoxin type F)BoNT/E (Botulinum neurotoxin type E)BoNT/A (Botulinum neurotoxin type A)BoNT/B (Botulinum neurotoxin type B)BoNT/C (Botulinum neurotoxin type C)BoNT/D (Botulinum neurotoxin type D)

Beyond the preview

Go deeper on anti-botulinum toxin recombinant hyperimmune.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-botulinum toxin recombinant hyperimmune.

Explore the full profile